Toni Choueiri, MD, Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute. In this video, he speaks about the ASCO GU 2022 Abstract – Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.
Podcast Toni Choueiri, MD @DrChoueiri @df_hcc @DanaFarbernews #ASCOGU22 #GU22 #RCC Phase III Follow-up KEYNOTE-564
By Editor